Isiah Thomas

Chief Executive Officer and Executive Chairman

Isiah Thomas, while forever known for his Hall of Fame career as a 12-time NBA All Star, two-time NBA champion, and inclusion as one of the 50 Greatest Players in NBA History, is an accomplished and highly regarded international business executive and investor with a portfolio of companies he has developed via Isiah International Inc. Mr. Thomas has previously served on the Chicago Stock Exchange’s Board of Governors, was a co-founder of the NBA’s Toronto Raptors, Popcorn Indiana, and is a member of the Board of Get-in Chicago, an organization focused on preventing gang violence in Chicago, since 2013.

His business interests include sports and entertainment, real estate, waste management, his cannabis and CBD products company, VESL Oils, and more. Notably, Mr. Thomas has developed a highly successful champagne business with Cheurlin Champagnes, where he has cultivated an excellent relationship with both the grower, employees and the French government. Mr. Thomas now uniquely owns genetics for the grapes produced for the champagne and has perfected an international import/export system for international distribution of the product.

Terry Buffalo


Terry Buffalo was appointed to serve as a director of One World Products on September 1, 2022. Mr. Buffalo established Buffalo Cannabis Advisors in 2022 and currently serves as its President, was the Chief Executive Officer and a director of American Cannabis Company from 2015 to 2021, and was the Chief Executive of First Midwest Securities, Inc. from 2002 to 2013. Prior to that, Mr. Buffalo was the President of American Investment Services from 1997 to 2002. In addition, Mr. Buffalo currently serves on the advisory board of Element Apothec since 2020. We believe that Mr. Buffalo’s investment banking and cannabis management experience qualifies him to serve as our director.

Dr. Kenneth Perego

Vice-Chairman of the Board and Chief Science Officer

Dr. Kenneth Perego, II, was a director of OWP Delaware prior to the Merger and was appointed to our Board of Directors pursuant to the Merger Agreement. He has been a practicing urologic surgeon in private practice since 2001 with an emphasis in urologic oncology and reconstructive urology. He has a strong clinical background in research and is focused on new drug discovery.